Neuca SA (NEU):企業の財務・戦略的SWOT分析

◆英語タイトル:Neuca SA (NEU) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0998
◆発行会社(調査会社):GlobalData
◆発行日:2020年1月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ポーランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Neuca SA (NEU) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Neuca SA (Neuca) is a provider of pharmaceutical and medical development solutions. The company offers wholesale distribution of pharmaceuticals and medical equipment to pharmacies and hospitals. It also involved in provision of pharmaceutical products under its own brand such as Synoptis Pharma and Synoptis Industrialand. The company also offers pharmaceuticals production, marketing, logistics, outpatient clinics network development, clinical trials and telemedicine. Neuca offers networking programs with independent pharmacies for the distribution of drugs. It provides primary healthcare services through its own network of outpatient care clinics. The company serves clients in Poland and abroad. Neuca is headquartered in Torun, Poland.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Neuca SA – Key Facts
Neuca SA – Key Employees
Neuca SA – Key Employee Biographies
Neuca SA – Major Products and Services
Neuca SA – History
Neuca SA – Company Statement
Neuca SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Neuca SA – Business Description
Business Segment: Outpatient Care Clinics, Clinical Trials and Telemedicine
Overview
Performance
Key Stats
Business Segment: Own Brands
Overview
Performance
Key Stats
Business Segment: Pharmacy Wholesale
Overview
Performance
Key Stats
Neuca SA – SWOT Analysis
SWOT Analysis – Overview
Neuca SA – Strengths
Neuca SA – Weaknesses
Neuca SA – Opportunities
Neuca SA – Threats
Neuca SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Neuca SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Neuca SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Neuca SA, Recent Deals Summary
Section 5 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Neuca SA, Key Facts
Neuca SA, Key Employees
Neuca SA, Key Employee Biographies
Neuca SA, Major Products and Services
Neuca SA, History
Neuca SA, Subsidiaries
Neuca SA, Key Competitors
Neuca SA, Ratios based on current share price
Neuca SA, Annual Ratios
Neuca SA, Annual Ratios (Cont...1)
Neuca SA, Annual Ratios (Cont...2)
Neuca SA, Interim Ratios
Neuca SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Neuca SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Neuca SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Neuca SA, Performance Chart (2014 - 2018)
Neuca SA, Ratio Charts
Neuca SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Neuca SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Neuca SA (NEU):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • StemBioSys Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary StemBioSys Inc (StemBioSys) is a biomedical company that concentrates on isolation, expansion and delivery of specialized adult stem cells. The company has developed high performance microenvironment for treating human diseases. Its HPME is an advanced stem cell culture system that creates n …
  • Bio-Path Holdings Inc (BPTH):企業の財務・戦略的SWOT分析
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • Shopping Centres Australasia Property Group RE Limited:企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • PNM Resources, Inc.:企業の戦略・SWOT・財務分析
    PNM Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary PNM Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Idera Pharmaceuticals Inc (IDRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the …
  • Factor Therapeutics Ltd (FTT):医療機器:M&Aディール及び事業提携情報
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd, is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor …
  • Ur-Energy Inc (URE):企業の財務・戦略的SWOT分析
    Ur-Energy Inc (URE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OncoTartis Inc-製薬・医療分野:企業M&A・提携分析
    Summary OncoTartis Inc (OncoTartis) is a biotechnology company with a focus on development of various treatments for various types of cancers. Its lead candidate OT-82, an orally available NicotinAMide Phosphoribosyl Transferase inhibitor, is being developed for treating broad range of leukemias and …
  • Great Western Bancorp Inc.:企業の戦略・SWOT・財務情報
    Great Western Bancorp Inc. - Strategy, SWOT and Corporate Finance Report Summary Great Western Bancorp Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Boubyan Petrochemical Co:企業の戦略・SWOT・財務分析
    Boubyan Petrochemical Co - Strategy, SWOT and Corporate Finance Report Summary Boubyan Petrochemical Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Nasdaq Inc (NDAQ):企業の財務・戦略的SWOT分析
    Nasdaq Inc (NDAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Leukemia & Lymphoma Society Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, an …
  • Central Iowa Power Cooperative:企業の戦略的SWOT分析
    Central Iowa Power Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • MegaChips Corporation (6875):企業の財務・戦略的SWOT分析
    MegaChips Corporation (6875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Petroleo Brasileiro S.A. (Petrobras):企業のM&A・事業提携・投資動向
    Petroleo Brasileiro S.A. (Petrobras) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Petroleo Brasileiro S.A. (Petrobras) Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Okinawa Cellular Telephone Company (9436):企業の財務・戦略的SWOT分析
    Okinawa Cellular Telephone Company (9436) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • FIncantieri SpA:企業の戦略・SWOT・財務情報
    FIncantieri SpA - Strategy, SWOT and Corporate Finance Report Summary FIncantieri SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SMS Pharmaceuticals Ltd (SMSPHARMA):製薬・医療:M&Aディール及び事業提携情報
    Summary SMS Pharmaceuticals Ltd (SMS Pharma) is a manufacturer of active pharmaceutical ingredients (APIs) and intermediates that develops offers anti-fungal, anti-ulcer, anti-migraine, anti-hypersensitive, anti-psychotic, anti-viral and other products. Its pipeline products include Ticagrelor, Clop …
  • WPPI Energy, Inc.:企業の戦略的SWOT分析
    WPPI Energy, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆